肝细胞癌免疫治疗超进展的FDG PET表现
FDG PET Findings of Hyperprogression During Immunotherapy in a Patient With Hepatocellular Carcinoma.
PubMed 文献 · Clin Nucl Med · 2020-01-01
超进展表现为免疫治疗后加速进展并导致更差结局,早期难以识别,随访评估一旦确诊应立即停止免疫治疗。
要点
- 免疫治疗可致部分患者超进展,表现为治疗后加速进展、结局更差。
- 随访确诊超进展后应立即停止免疫治疗。
临床怎么用
- 超进展早期难以识别,随访评估确诊后应立即停止免疫治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although immunotherapy is a successful approach in oncology, it might be detrimental to some patients. In the condition of hyperprogression, patients experience accelerated progression after immunotherapy, resulting in a worse outcome. Hyperprogression may be difficult to be identified in the early stage. Once the diagnosis is confirmed in the follow-up evaluation, the immunotherapy should be stopped immediately. In this case, we report a hyperprogression patient during combined immunotherapy toward metastatic hepatocellular carcinoma observed by serial F-FDG PET.
来源:Clin Nucl Med,查看原文。版权归原作者所有。
引用
- Wang J, Wang X, Yang X, et al. FDG PET Findings of Hyperprogression During Immunotherapy in a Patient With Hepatocellular Carcinoma. Clin Nucl Med. 2020. PMID: 31789917. doi:10.1097/RLU.0000000000002849
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。